Nectar Lifesciences Limited has entered into a Business Transfer Agreement (BTA) with Ceph Lifesciences Private Limited to divest its core active pharmaceutical ingredients (API) and formulations division for ₹1,270 crore. The deal, executed on a slump sale basis, marks a significant step in Nectar’s broader business restructuring strategy.
Menthol Business Also Sold Under Separate Agreement
In addition to the main deal, Nectar Lifesciences has signed an Asset Purchase Agreement (APA) to sell its menthol business assets to Ceph Lifesciences for ₹20 crore. This move is part of the company’s effort to streamline its operations and focus on higher-growth segments.
Leadership Focused on Agility and Innovation
Sanjiv Goyal, Promoter and Chairman of Nectar Lifesciences, said, “By divesting mature segments of our business, we are laying the foundation for a focused and agile organization geared towards innovation and long-term value creation”.
